Brookstone Capital Management Has $2.47 Million Holdings in Pfizer Inc. (NYSE:PFE)

Brookstone Capital Management cut its stake in Pfizer Inc. (NYSE:PFE) by 79.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,030 shares of the biopharmaceutical company’s stock after selling 342,976 shares during the period. Brookstone Capital Management’s holdings in Pfizer were worth $2,471,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Clifford Swan Investment Counsel LLC boosted its holdings in Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock valued at $12,007,000 after purchasing an additional 18,611 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in shares of Pfizer during the 4th quarter worth about $255,000. Cantor Fitzgerald Investment Advisors L.P. bought a new position in shares of Pfizer during the 4th quarter worth about $16,166,000. Finally, KLCM Advisors Inc. lifted its holdings in shares of Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.4 %

PFE opened at $27.80 on Friday. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $157.53 billion, a PE ratio of -463.26, a PEG ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The firm has a 50-day moving average price of $27.81 and a two-hundred day moving average price of $27.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter last year, the company posted $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.